Merck, Pfizer Partner Diabetes Drug Gets FDA Ok

Source: Reuters

Dec 21, 2017

Steglatro, a new drug developed by Merck and Pfizer, won U.S. approval to treat type II diabetes.

The oral drug, which is an SGLT2 inhibitor, will compete with J&J’s Invokana, AstraZeneca’s Farxiga, and Eli Lilly and Boehringer Ingelheim’s Jardiance.

Steglatro was approved as a single therapy and in fixed-dose combinations with Merck’s diabetes drug Januvia or with metformin, an older generic treatment

Read the press release


Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.


No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments